Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
SL

NASDAQ · SLXN

Silexion Therapeutics Ltd.

Healthcare · Biotechnology

$0.15

Up+$0.00 (+2.04%)

Updated Nov 2, 2026, 6:42 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.69M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.14 – $5.45
Volume
741.91K
Avg. volume
205.66K

Price performance · SLXN

SLXN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

SLXN closed at $0.15 after 20 trading sessions, down 45.41% for the selected period.

Last close
$0.15
Period change
-45.41%
Period low
$0.14
Period high
$0.27
Daily close
View OHLC price history
SLXN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.1424$0.17$0.1401$0.1452741.91K
Oct 29, 2026$0.158$0.1754$0.1416$0.1423597.47K
Oct 28, 2026$0.1695$0.1695$0.151$0.1532486.72K
Oct 27, 2026$0.1786$0.1791$0.1602$0.1657975.39K
Oct 26, 2026$0.1746$0.1839$0.168$0.17463.42M
Oct 23, 2026$0.169$0.195$0.161$0.18892.81M
Oct 22, 2026$0.169$0.1799$0.1595$0.1652544.92K
Oct 21, 2026$0.171$0.171$0.16$0.165289.19K
Oct 20, 2026$0.153$0.1737$0.153$0.15381.12M
Oct 19, 2026$0.164$0.1831$0.1416$0.1535.12M
Oct 16, 2026$0.194$0.194$0.152$0.153836.38K
Oct 15, 2026$0.1707$0.195$0.1675$0.1892.83M
Oct 14, 2026$0.18$0.1804$0.1637$0.171704.86K
Oct 13, 2026$0.188$0.1937$0.163$0.1762.09M
Oct 12, 2026$0.2082$0.2082$0.1766$0.17821.27M
Oct 9, 2026$0.2297$0.232$0.2079$0.2146821.09K
Oct 8, 2026$0.246$0.2499$0.222$0.23491.51M
Oct 7, 2026$0.247$0.2584$0.2457$0.25361.08M
Oct 6, 2026$0.2686$0.2686$0.253$0.2628999.25K
Oct 5, 2026$0.2605$0.27$0.257$0.2661.23M

Latest SLXN news

The latest Smart Investors Daily articles mentioning SLXN.

Stock researchCompany · Overview

SLXN research

Overview

Company profile and research snapshot.

Company profile

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SLXN recent ratings
DateFirmRatingTarget
Dec 15, 2025Litchfield HillsBuy—
Mar 20, 2025Maxim GroupBuy—
Nov 1, 2024Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer Integrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor stroma with subcutaneous dosing; first patient treated at Tel Aviv Sourasky Medical Center (Ichilov) Grand Cayman, Cayman Islands and Ramat Gan, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By